AstraZeneca
-
This week, shares in AstraZeneca fell more than 4 percent after the disappointing outcomes of a data abstract on its experimental precision drug, datopotamab deruxtecan, used in lung cancer patients in a late-stage trial. The abstract was published ahead of the European Society for Medical Oncology’s (ESMO) congress, which will begin in Madrid on October…
-
Patients developed blood clotting conditions after receiving the AstraZeneca COVID-19 vaccine at a “similar” rate to those who received the Pfizer/BioNTech jab, say researchers. A team of researchers from Spain, the UK and the Netherlands compared data from over 1.3 million people vaccinated against COVID in Catalonia, looking for evidence of blood clotting conditions that…
-
The European Union’s drug regulatory agency said Thursday that the AstraZeneca vaccine doesn’t increase the overall incidence of blood clots and that the benefits of using it outweigh the possible risks, paving the way for European countries to resume dispensing the shots. France, Italy and Germany promptly announced they will start using the vaccine again…
-
Australia will receive the first doses of an AstraZeneca and Oxford University COVID-19 vaccine in January 2021 if trials prove successful after Canberra agreed a deal to purchase a second potential vaccine, Prime Minister Scott Morrison said on Monday. Australia said in August it had signed a preliminary agreement with AstraZeneca for enough doses for…
You must be logged in to post a comment.